The molecular basis of the interplay between endothelin-1 and nitric oxide and its relevance for atherosclerosis and arterial and pulmonary hypertension

Vascular Disease Prevention

Volumn 2, Issue 1, 2005, Pages 53-66

  Seccia, Teresa M ^a,b   Maiolino, Giuseppe ^a   Pessina, Achille C ^a   Rossi, Gian Paolo ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Arterial hypertension; Atherosclerosis; Coronary artery disease; Endothelin; Nitric oxide; Pulmonary hypertension

Indexed keywords

CYTOKINE; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL TYPE; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REGULATORY MECHANISM; REVIEW; SHEAR STRESS; STIMULATION; SYNTHESIS; VASOCONSTRICTION;

EID: 20144379881     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567270052774430     Document Type: Review

References (174)

1. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
2. Rubanyi GM and Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46, 325-415, 1994.
3. Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996; 72: 109-148.
4. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
5. Rubino A, Loesch A, Burnstock G. Nitric oxide and endothelin-1 in coronary and pulmonary circulation. Int Rev Cytol 1999; 189: 59-93.
6. Dussaule JC, Tharaux PL, Boffa JJ, Ardaillou R, Chatziantoniou C. Nephrologie 1998; 19: 437-441.
7. Warner TD. Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 1999; 26: 247-252.
8. Lavallee M, Takamura M, Parent R, Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 2001; 6: 265-276.
9. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003; 8: 107-115.
10. Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J Hypertens 1998; 16: 657-664.
11. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
12. Nakano A, Kishi F, Minami K, et al. Selective conversion of big endothelins to tracheal smooth muscle- constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997; 159: 1987-1992.
13. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular Matrix Metalloproteinase-2 Cleaves Big Endothelin-1 Yielding a Novel Vasoconstrictor. Circ Res 1999; 85: 906-911.
14. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186: 867-873.
15. Jagroop IA, Mikhailidis DP. Affect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Platelets 2000; 11: 272-277.
16. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
17. Kennedy RL, Haynes WG, Webb DJ. Endothelins as regulators of growth and function in endocrine tissues. Clin Endocrinol 1993; 39: 259-265.
18. Rubanyi GM, Botelho LH. Endothelins. FASEB J 1991; 5: 2713-2720.
19. Belloni A, Rossi GP, Andreis PG, et al. Endothelin adrenocortical secretagogue affect is mediated by the B receptor in rats. Hypertension 1996; 27: 1153-1159.
20. Rossi GP, Albertin G, Neri G, et al. Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes. J Clin Endocrinol Metab 1997; 82: 3445-3449.
21. 2+ in human adrenocortical carcinoma. Endocrinology 1997; 138: 4421-4426.
22. Mazzocchi G, Rossi GP, Rebuffat P, et al. Endothelin-1 stimulates deoxyribonucleic acid synthesis and cell proliferation in rat adrenal zona glomerulosa, acting through an endothelin A receptor coupled with protein kinase C- and tyrosine kinase-dependent signaling pathways. Endocrinology 1997; 138: 2333-2338.
23. Mazzocchi G, Rossi GP, Malendowicz LK, Champion HC, Nussdorfer GG. Endothelin-1 [1-31], acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett 1 2000; 487: 194-198.
24. Nussdorfer GG, Rossi GP, Malendowicz LK, Mazzocchi G. Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol Rev 1999; 51: 1-35.
25. Rossi GP, Belloni AS, Nussdorfer GG, Pessina AC. Endothelin-1 and the adrenal gland. J Cardiovasc Pharmacol 2000; 35: 18-20.
26. Marletta MA, Hurshman AR, Rusche KM. Catalysis by nitric oxide synthase. Curr Opin Chem Biol 1998; 2: 656-663.
27. Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res 1999; 43: 274-278.
28. Andrew PJ, Mayer B. Enzymatic function of nitric oxide syntheses. Cardiovasc Res 1999; 43: 521-531.
29. MacAllister RJ, Rambausek MH, Vallance P, et al. Concentration of dimethyl-L-arginine in the plasma of patients with end- stage renal failure. Nephrol Dial Transplant 1996; 11: 2449-2452.
30. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93: 13176-13181.
31. Rudic RD, Shesely EG, Maeda N, et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998; 101: 731-736.
32. Wever RM, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.
33. Gow AJ, Buerk DG, Ischiropoulos H. A novel reaction mechanism for the formation of S-nitrosothiol in vivo. J Biol Chem 1997; 272: 2841-2845.
34. Kharitonov VG, Sundquist AR, Sharma VS. Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen. J Biol Chem 1995; 270: 28158-28164.
35. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
36. Benatti L, Fabbrini MS, Patrono C. Regulation of endothelin-1 biosynthesis. Ann N Y Acad Sci 1994; 714: 109-121.
37. Emori T, Hirata Y, Imai T, et al. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem Pharmacol 1992; 44: 2409-2411.
38. Emori T, Hirata Y, Ohta K, et al. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991; 18: 165-170.
39. Boulanger CM, Luscher TF. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res 1991; 68: 1768-1772.
40. Lee ME, Dhady MS, Temizer DH, et al. Regulation of endothelin-1 gene expression by Fos and Jun. J Biol Chem 1991; 266: 19034-19039.
41. Curran T, Franza BRJ. Fos and Jun: the AP-1 connection. Cell 1988; 55: 395-397.
42. Marsden PA, Heng HH, Scherer SW, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-17488.
43. Wang DL, Wung BS, Peng YC, Wang JJ. Mechanical strain increases endothelin-1 gene expression via protein kinase C pathway in human endothelial cells. J Cell Physiol 1995; 163: 400-406.
44. Fadel BM, Boutet SC, Quertermous T. Endothelial cell-specific regulation of the murine endothelin-1 gene. J Cardiovasc Pharmacol 2000; 35: 7-11.
45. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 2000; 86: 347-354.
46. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol 1999; 31: 5-14.
47. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C abd cGMP in cultured endothelial cells. Am J Physiol 1993; 264: H150-H156.
48. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A 1993; 90: 5999-6003.
49. Malek AM, Lee IW, Alper SL, Izumo S. Regulation of endothelin-1 gene expression by cell shape and the microfilament network in vascular endothelium. Am J Physiol 1997; 273: C1764-C1774.
50. Malek AM, Zhang J, Jiang J, Alper SL, Izumo S. Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J Mol Cell Cardiol 1999; 31: 387-399.
51. Ikeda M, Kohno M, Takeda T. Endothelin production in cultured mesangial cells of spontaneously hypertensive rats. Hypertension 1995; 25: 1196-1201.
52. Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3′,5′- monophosphate. Hypertension 1992; 19: 320-325.
53. Kohno M, Kano H, Horio T, et al. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension 1995; 25: 1185-1190.
54. Kohno M, Murakawa K, Yokokawa K et al. Production of endothelin by cultured porcine endothelial cells: modulation by adrenaline. J Hypertens Suppl 1989; 7: S130-S131.
55. Kohno M, Yasunari K, Yokokawa K, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991; 87: 1999-2004.
56. Morey AK, Razandi M, Pedram A, et al. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J 1998; 330: 1097-1105.
57. Prins BA, Hu RM, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-11944.
58. Yokokawa K, Kohne M, Mandal AK, et al. Heparin suppresses endothelin-1 peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats. J Am Soc Nephrol 1994; 4: 1683-1689.
59. Yokokawa K, Kohno M, Minami M, et al. Heparin suppresses cyclosporine-induced endothelin-1 synthesis in rat endothelial cells. J Cardiovasc Pharmacol 1998; 31 Suppl 1: S460-3: S460-S463.
60. Papapetropoulos A, Rudic RD, Sessa WC. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 1999; 43: 509-520.
61. Kone BC. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand 2000; 168: 27-31.
62. Bloch KD. Regulation of endothelial NO synthase mRNA stability: RNA-binding proteins crowd on the 3′-untranslated region. Circ Res 1999; 85: 653-655.
63. Forstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 773-790.
64. Nakayama M, Yasue H, Yoshimura M, et al. T-786 - >C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-2870.
65. Rossi GP, Cesari M, Zanchetta M, et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 2003; %19;41: 930-937.
66. Rossi GP, Taddei S, Virdis A, et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41: 938-945.
67. Lee ME, Bloch KD, Clifford JA, Quertermous T. Functional analysis of the Endothelin-1 gene promoter: Evidence for an endothelial cell specific cis-acting sequence. J Biol Chem 1990; 265: 10446-10450.
68. Lee ME, de la Monte SM, Ng SC, Bloch KD, Quertermous T. Expression of the potent vasoconstrictor endothelin in the human central nervous system. J Clin Invest 1990; 86: 141-147.
69. Wilson DB, Dorfman DM, Orkin SH. A nonerythroid GATA-binding protein is required for function of the human preproendothelin-1 promoter in endothelial cells. Mol Cell Endocrinol 1990; 10: 4854-4862.
70. Bloch KD, Friedrich SP, Lee ME, et al. Structural organization and chromosomal assignment of the gene encoding endothelin. J Biol Chem 1989; 264: 10851-10857.
71. McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal affects in salt-deplete men. J Cardiovasc Pharmacol 1996; 28: 101-106.
72. McIntyre M, Bohr DF, Dominiczak AF. Endothelial Function in Hypertension: The Role of Superoxide Anion. Hypertension 1999; 34: 539-545.
73. Hughes AK, Stricklett PK, Padilla E, Kohan DE. Affect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 1996; 49: 181-189.
74. Robinson LJ, Weremowicz S, Morton CC, Michel T. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics 1994; 19: 350-357.
75. Venema RC, Nishida K, Alexander RW, Harrison DG, Murphy TJ. Organization of the bovine gene encoding the endothelial nitric oxide synthase. Biochim Biophys Acta 1994; 1218: 413-420.
76. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000; 269: 713-717.
77. Ishizuka T, Takamizawa-Matsumoto M, Suzuki K, Kurita A. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur J Pharmacol 1999; 369: 237-245.
78. Cheng TH, Shih NL, Chen SY, Wang DL, Chen JJ. Reactive oxygen species modulate endothelin-1-induced c-fos gene expression in cardiomyocytes. Cardiovasc Res 1999; 41: 654-662.
79. Gallois C, Habib A, Tao J, et al. Role of NF-kappaB in the antiproliferative affect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem 1998; 273: 23183-23190.
80. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-264.
81. Peng HB, Libby P, Liao JK. Induction and stabilization of 1 kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270: 14214-14219.
82. Wilson SH, Caplice NM, Simari RD, et al. Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 2000; 148: 23-30.
83. Ohkita M, Takaoka M, Shiota Y, Nojiri R, Matsumura Y. Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor kappa B. Clin Sci (Lond) 2002; 103 Suppl 48: 68S-71S.
84. Montalescot G, Viossat I, Chabrier PE, et al. Endothelin-1 in patients with coronary heart disease undergoing cardiac catheterization. J Am Coll Cardiol 1994; 24: 1236-1241.
85. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
86. Ikeda U, Shimpo M, Murakami Y, Shimada K. Peroxisome proliferator- activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells. Hypertension 2000; 35: 1232-1236.
87. Iglarz M, Touyz RM, Amiri F, et al. Affect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23: 45-51.
88. Namiki A, Hirata Y, Ishikawa M, et al. Endothelin-1- and endothelin-3-induced vasorelaxation via common generation of endothelium-derived nitric oxide. Life Sci 1992; 50: 677-682.
89. Tsukahara H, Ende H, Magazine HI, Bahou WF, Goligorsky MS. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 1994; 269: 21778-21785.
90. Beck KF, Mohaupt MG, Sterzel RB. Endothelin-1 inhibits cytokine-stimulated transcription of inducible nitric oxide synthase in glomerular mesangial cells. Kidney Int 1995; 48: 1893-1899.
91. Ikeda U, Yamamoto K, Maeda Y, et al. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997; 29: 65-69.
92. Hirahashi J, Nakaki T, Hishikawa K, et al. Endothelin-1 inhibits induction of nitric oxide synthase and GTP cyclohydrolase 1 in rat mesangial cells. Pharmacology 1996; 53: 241-249.
93. Beck KF, Sterzel RB. Cloning and sequencing of the proximal promoter of the rat iNOS gene: activation of NFkappaB is not sufficient for transcription of the iNOS gene in rat mesangial cells. FEBS Lett 1996; 394: 263-267.
94. Kanno K, Hirata Y, Imai T, Iwashina M, Marumo F. Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells. Am J Physiol 1994; 267: H2318-H2324.
95. Iwashina M, Hirata Y, Imai T, Sato K, Marumo F. Molecular cloning of endothelial, inducible nitric oxide synthase gene from rat aortic endothelial cell. Eur J Biochem 1996; 237: 668-673.
96. Balligand JL, Ungureanu-Longrois D, Simmons WW, et al. Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1 beta and IFN-gamma. Am J Physiol 1995; 268: H1293-H1303.
97. Joly GA, Schini VB, Vanhoutte PM. Balloon injury and interleukin-1 beta induce nitric oxide synthase activity in rat carotid arteries. Circ Res 1992; 71: 331-338.
98. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993; 191: 1081-1088.
99. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91: 941-947.
100. Hasdai D, Holmes DRJ, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997; 95: 357-362.
101. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
102. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587-590.
103. Takada K, Matsumura Y, Dohmen S, et al. Endothelin-1 secretion from cultured vascular endothelial cells of DOCA- salt hypertensive rats. Life Sci 1996; 59: L111-L116.
104. Rizvi MA, Myers PR. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol 1997; 29: 1779-1789.
105. Doshi SN, Goodfellow J, Lewis MJ, McDowell IF. Homocysteine and endothelial function. Cardiovasc Res 1999; 42: 578-582.
106. Eikelboom JW, Lonn E, Genest JJ, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
107. Ming Z, Parent R, Thorin E, Lavallee M. Endothel in-dependent tone limits acetylcholine-induced dilation of resistance coronary vessels after blockade of NO formation in conscious dogs. Hypertension 1998; 32: 844-848.
108. Gellai M, Fletcher T, Pullen M, Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol 1996; 271: R254-R261.
109. Verhaar MC, Strachan FE, Newby DE. et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752-756.
110. Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000; 35: 1237-1241.
111. Usui M, Egashira K, Kitamoto S, et al. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1999; 34: 546-551.
112. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-310.
113. Romero JC, Reckelhoff JF. State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-949.
114. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
115. Rossi GP, Sacchetto A, Rizzoni D, et al. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic TGR(mRen2)27 rats via adrenocortical steroid-independent mechanisms. Arteriosci Thromb Vasc Biol 2000; 20: 949-956.
116. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ. Endothelin in the kidney in malignant phase hypertension. Hypertension 1995; 26: 925-931.
117. Bohlender J, Gerbaulet S, Kramer J, et al. Synergistic affects of AT(I) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000; 35: 992-997.
118. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999; 43: 300-307.
119. Orth SR, Esslinger JP, Amann K, et al. Nephroprotection of an ETA-Receptor Blocker (LU 135252) in Salt-Loaded Uninephrectomized Stroke-Prone Spontaneously Hypertensive Rats. Hypertension 1998; 31: 995-1001.
120. Orth SR, Odoni G, Amann K, et al. The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J Am Soc Nephrol 1999; 10: 387-391.
121. Tharaux PL, Chatziantoniou C, Casellas D, et al. Vascular endothelin-1 gene expression and synthesis and affect on renal type 1 collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999; 99: 2185-2191.
122. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Cooperation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999; 26: 269-271.
123. Barton M, Haudenschild CC, d'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998; 95: 14367-14372.
124. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
125. Drexler H, Zeiher AM. Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension 1991; 18: 1190-1199.
126. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-1992.
127. Lerman A, Holmes DR, Jr., Bell MR, et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92: 2426-2431.
128. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
129. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Affects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652-662.
130. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-762.
131. Rossi GP, Colonna S, Pavan E, et al. Endothelin-1 and its mRNA in the wall layers of human arteries Ex vivo. Circulation 1999; 99: 1147-1155.
132. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
133. Salomone OA, Elliott PM, Calvino R, Holt D, Kaski JC. Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol 1996; 28: 14-19.
134. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 1762-1767.
135. Panza JA, Quyyumi AA, Brush JEJ, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
136. Taddei S, Virdis A, Ghiadoni L, Salvetti A. The role of endothelium in human hypertension. Curr Opin Nephrol Hypertens 1998; 7: 203-209.
137. Quyyumi AA, Mulcahy D, Andrews NP, et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation 1997; 95: 104-110.
138. Rossi GP, Seccia TM, Albertin G, Pessina AC. Measurement of endothelin: clinical and research use. Ann Clin Biochem 2000; 37: 608-626.
139. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-16068.
140. Taddei S, Virdis A, Ghiadoni L, et al. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-1683.
141. Liu Z, Wildhirt SM, Weismuller S, et al. Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. Atherosclerosis 1998; 140: 1-14.
142. Ravalli S, Szabolcs M, Albala A, Michler RE, Cannon PJ. Endothelin-1 peptide expression in transplant coronary artery disease. Transplant Proc 1997; 29: 2577-2578.
143. Okada K, Nishida Y, Murakami H, et al. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative affects of bosentan, a nonselective endothelin receptor antagonist. Circulation 1998; 97: 2346-2351.
144. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002; 39: 60-69.
145. Wang J, Seyedi N, Xu XB, Wolin MS, Hintze TH. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol 1994; 266: H670-H680.
146. Smith CJ, Sun D, Hoegler C, et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996; 78: 58-64.
147. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-1601.
148. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84: 1589-1596.
149. Winlaw DS, Smythe GA, Keogh AM, et al. Increased nitric oxide production in heart failure. Lancet 1994; 344: 373-374.
150. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-2430.
151. Habib F, Dutka D, Crossman D, Oakley CM, Cleland JG. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet 1994; 344: 371-373.
152. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-1586.
153. Iwanaga Y, Kihara Y, Hasegawa K, et al. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 1998; 98: 2065-2073.
154. Ruetten H, Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 1997; 48: 675-688.
155. Pacher R, Bergler Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71: 1293-1299.
156. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: affect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96: 1976-1982.
157. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1- mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-736.
158. Sutsch G, Bertel O, Kiowski W. Acute and short-term affects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997; 10: 717-725.
159. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98: 2262-2268.
160. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic affects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103: 973-980.
161. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003; 41: 204-210.
162. O'Connor CM, Gattis WA, Adams KF Jr., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). Am Heart J 2003; 145: S58-S59.
163. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003; 108: 2184-2190.
164. Louis AA, Manousos IR, Coletta AP, Clark AL, Cleland JG. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiograpliy. AzimiLide post-Infarct survival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. Eur J Heart Fail 2002; 4: 111-116.
165. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral affects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002; 106: 2666-2672.
166. Coletta AP, Louis AA, Clark AL, Nikitin N, Cleland JG. Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II. Eur J Heart Fail 2002; 4: 661-666.
167. Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998; 135: 614-620.
168. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-1554.
169. Rubin LJ, Badeseh DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
170. Campbell AI, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1999; 21: 567-575.
171. Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995; 92: 1539-1545.
172. Zamora MA, Dempsey EC, Walchak SJ, Stelzner TJ. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993; 9: 429-433.
173. Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol 2000; 35: 49-54.
174. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic affects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102: 411-418.